chronic graft versus host disease
Haematology · 2021–2022
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| ruxolitinib Treatment of patients aged ≥12 years with moderate to severe chronic graft-versus-host disease (cGVHD) who are steroid refractory, dependent, or intolerant;… | Nov 2022 | Recommended with restriction | input received Leukaemia Foundation · Rare Cancers Australia |
| methoxsalen Treatment of steroid dependent, steroid intolerant or steroid refractory chronic graft versus host disease (cGVHD) in patients following allogeneic… | Sep 2021 | Recommended | none received |
| methoxsalen Treatment of steroid dependent, steroid intolerant or steroid refractory chronic graft versus host disease (cGVHD) following allogeneic haematopoietic stem… | Jul 2021 | Deferred | none received |
Who spoke
Leukaemia Foundation · Rare Cancers Australia
What the PBS pays
$114M in government benefit over 2024–25, across 26,104 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| ruxolitinib | $113.4M |
| methoxsalen | $0.3M |
Appraised elsewhere
NICE, in England and Wales, has appraised 3 technologies for this condition, recommending 1 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| ruxolitinibRuxolitinib for treating moderate to severe chronic graft versus host disease after an allogeneic stem cell transplant in people 28 days to 17 years (terminated appraisal) | TA1132 | terminated | 2026-02 |
| belumosudilBelumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over | TA949 | recommended restricted | 2024-02 |
| ruxolitinibRuxolitinib for treating chronic graft versus host disease refractory to corticosteroids (terminated appraisal) | TA840 | terminated | 2022-11 |
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| axatilimabNIKTIMVO axatilimab 22 mg / 0.44 mL solution for injection glass vial | 2026 | 2 |
| belumosudilREZUROCK belumosudil 200 mg (as mesilate) film-coated tablets bottle | 2021 | 1 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.